ArticleSisli Etfal Hastanesi tip bulteni2026
Serum Zonulin Levels in Patients with Heroin Addiction.
Article in Sisli Etfal Hastanesi tip bulteni, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Opioid use has been associated with alterations in gut-brain axis signaling and intestinal barrier function. Zonulin, a key regulator of intestinal permeability, has been implicated in various neuropsychiatric and inflammatory conditions; however, its role in heroin addiction and remission remains poorly understood. This study aimed to investigate serum zonulin levels in patients with heroin addiction (HA) during active heroin use (AHU) and remission (R) and to compare these levels with those of healthy controls (C). Methods: A total of 104 male participants were included: patients with AHU, patients in remission under buprenorphine/naloxone maintenance treatment, and C. Serum zonulin levels were measured using an enzyme-linked immunosorbent assay. Group comparisons and correlation analyses were performed, and receiver operating characteristic (ROC) analysis was used to evaluate the discriminatory value of zonulin. Results: The scores of addiction diagnostic criteria, the severity of craving, and the total API score were significantly higher in the AHU group than in the R group. The difference between the groups was significant when the R, AHU, and C groups were compared for zonulin levels (p=0.02). This difference was due to zonulin levels being higher in the R group than in the C group. When the HA (R+AHU) and C groups were compared for zonulin levels, zonulin levels were significantly higher in the HA group than in the C group (p=0.00). In the ROC analysis, the highest area under the curve (AUC) values were obtained in the R-C group comparison and the HA-C group comparison (AUC=0.683 and AUC=0.650, respectively). Conclusion: These findings suggest that increased intestinal permeability, as reflected by elevated serum zonulin levels, may persist during the remission phase of heroin addiction. However, given the cross-sectional design and the fact that remission was defined as a medication-stabilized state under buprenorphine treatment, these results should be interpreted cautiously. Longitudinal studies incorporating follow-up assessments and gut microbiota analyses are warranted to clarify the temporal dynamics and clinical significance of zonulin alterations in heroin addiction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.